Pfizer Inc. $PFE Shares Sold by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 9.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 301,876 shares of the biopharmaceutical company’s stock after selling 29,865 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Pfizer were worth $8,477,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Brighton Jones LLC lifted its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares in the last quarter. United Bank increased its position in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after acquiring an additional 6,415 shares during the last quarter. Sei Investments Co. increased its position in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock worth $63,889,000 after acquiring an additional 631,523 shares during the last quarter. Finally, HUB Investment Partners LLC lifted its stake in shares of Pfizer by 45.3% in the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock worth $2,480,000 after acquiring an additional 31,896 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 1.7%

Shares of Pfizer stock opened at $23.64 on Friday. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $134.71 billion, a P/E ratio of 18.04 and a beta of 0.34. Pfizer Inc. has a fifty-two week low of $23.11 and a fifty-two week high of $28.75. The business has a 50-day moving average price of $26.00 and a 200 day moving average price of $26.30.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, sell-side analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Ibrance for frontline maintenance use in HR-positive, HER2-positive advanced or metastatic breast cancer, giving Pfizer a new label expansion that could support sales and help offset pressure from older drugs. FDA Approves Pfizer’s IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
• Positive Sentiment: Pfizer announced its quarterly dividend remains at $0.43 per share, reinforcing the company’s shareholder-return profile and highlighting management’s commitment to its payout. Pfizer Declares Third-Quarter 2026 Dividend
• Positive Sentiment: Pfizer was dismissed from a U.S. states’ generic drug price-fixing lawsuit, removing a potential legal overhang. Pfizer dismissed from US states’ drug price-fixing lawsuit
• Neutral Sentiment: Pfizer Ventures helped lead a $62 million Series B for Oblenio Bio, showing continued investment in early-stage biotech opportunities, though the deal is unlikely to move the stock near term. Oblenio Bio Closes $62 Million Series B
• Negative Sentiment: Earlier reports said Pfizer’s Phase 3 lung cancer data for sigvotatug vedotin failed to show a statistically significant overall survival benefit, fueling concerns about its long-term oncology pipeline and helping explain the recent weakness in PFE. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative
• Negative Sentiment: Comparison pieces weighing AbbVie versus Pfizer and Lilly versus Pfizer suggest investors still see Pfizer as the slower-growth big pharma name relative to peers, which can keep valuation pressure on the stock. AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on PFE shares. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Sunday, June 21st. CICC Research began coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Bank of America decreased their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $28.82.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.